Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up

Abstract Purpose To evaluate the efficacy of concurrent chemoradiotherapy (CCRT) in subgroups of stage III nasopharyngeal carcinoma (NPC) in the context of intensity-modulated radiotherapy (IMRT). Methods A total of 272 patients with stage III NPC who underwent IMRT with or without concurrent chemot...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lei Wang, Zheng Wu, Wanqin Cheng, Dehuan Xie, Feifei Lin, Liangping Xia, Yong Su
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Stage III Nasopharyngeal carcinoma Intensity-modulated radiotherapy Concurrent chemoradiotherapy Survival outcome Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d57305fc8e9644b699be7a0a99810f3e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d57305fc8e9644b699be7a0a99810f3e
record_format	dspace
spelling	oai:doaj.org-article:d57305fc8e9644b699be7a0a99810f3e2021-11-08T10:45:01ZEfficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up10.1186/s13014-021-01929-91748-717Xhttps://doaj.org/article/d57305fc8e9644b699be7a0a99810f3e2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13014-021-01929-9https://doaj.org/toc/1748-717XAbstract Purpose To evaluate the efficacy of concurrent chemoradiotherapy (CCRT) in subgroups of stage III nasopharyngeal carcinoma (NPC) in the context of intensity-modulated radiotherapy (IMRT). Methods A total of 272 patients with stage III NPC who underwent IMRT with or without concurrent chemotherapy were retrospectively reviewed. Clinicopathological features were evaluated by a Cox regression model to identify independent prognostic factors. Survival outcomes were assessed using the Kaplan–Meier method and log-rank test. Results The median follow-up time was 108 months. The 10-year locoregional-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 87.8%, 80.7%, 68.8%, and 74.9%, respectively. Multivariate analysis showed that the N classification was significantly associated with DMFS (hazard ratio [HR] 3.616, 95% confidence interval [CI] 1.387–9.428, P = 0.009), DFS (HR 2.417, 95% CI 1.291–4.423, P = 0.006), and OS (HR 3.024, 95% CI 1.385–6.602, P = 0.005). In patients with T1-3N2 disease, CCRT was associated with improved 10-year LRFS (89.6% vs. 65.4%, P = 0.005), DFS (71.9% vs. 39.4% P = 0.001) and OS (80.0% vs. 50.5%, P = 0.004) compared with IMRT alone. However, in patients with T3N0-1 disease, no significant survival differences were observed between patients treated with IMRT alone and CCRT (P > 0.05). Conclusions CCRT is an effective therapy in stage III NPC, especially for patients with N2 disease, but IMRT alone may be adequate for N0-1 disease. Individualized treatment strategies are essential for patients with varying disease risks.Lei WangZheng WuWanqin ChengDehuan XieFeifei LinLiangping XiaYong SuBMCarticleStage IIINasopharyngeal carcinomaIntensity-modulated radiotherapyConcurrent chemoradiotherapySurvival outcomeMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENRadiation Oncology, Vol 16, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Stage III Nasopharyngeal carcinoma Intensity-modulated radiotherapy Concurrent chemoradiotherapy Survival outcome Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Stage III Nasopharyngeal carcinoma Intensity-modulated radiotherapy Concurrent chemoradiotherapy Survival outcome Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lei Wang Zheng Wu Wanqin Cheng Dehuan Xie Feifei Lin Liangping Xia Yong Su Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
description	Abstract Purpose To evaluate the efficacy of concurrent chemoradiotherapy (CCRT) in subgroups of stage III nasopharyngeal carcinoma (NPC) in the context of intensity-modulated radiotherapy (IMRT). Methods A total of 272 patients with stage III NPC who underwent IMRT with or without concurrent chemotherapy were retrospectively reviewed. Clinicopathological features were evaluated by a Cox regression model to identify independent prognostic factors. Survival outcomes were assessed using the Kaplan–Meier method and log-rank test. Results The median follow-up time was 108 months. The 10-year locoregional-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 87.8%, 80.7%, 68.8%, and 74.9%, respectively. Multivariate analysis showed that the N classification was significantly associated with DMFS (hazard ratio [HR] 3.616, 95% confidence interval [CI] 1.387–9.428, P = 0.009), DFS (HR 2.417, 95% CI 1.291–4.423, P = 0.006), and OS (HR 3.024, 95% CI 1.385–6.602, P = 0.005). In patients with T1-3N2 disease, CCRT was associated with improved 10-year LRFS (89.6% vs. 65.4%, P = 0.005), DFS (71.9% vs. 39.4% P = 0.001) and OS (80.0% vs. 50.5%, P = 0.004) compared with IMRT alone. However, in patients with T3N0-1 disease, no significant survival differences were observed between patients treated with IMRT alone and CCRT (P > 0.05). Conclusions CCRT is an effective therapy in stage III NPC, especially for patients with N2 disease, but IMRT alone may be adequate for N0-1 disease. Individualized treatment strategies are essential for patients with varying disease risks.
format	article
author	Lei Wang Zheng Wu Wanqin Cheng Dehuan Xie Feifei Lin Liangping Xia Yong Su
author_facet	Lei Wang Zheng Wu Wanqin Cheng Dehuan Xie Feifei Lin Liangping Xia Yong Su
author_sort	Lei Wang
title	Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
title_short	Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
title_full	Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
title_fullStr	Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
title_full_unstemmed	Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up
title_sort	efficacy of concurrent chemoradiotherapy in subgroups of stage iii nasopharyngeal carcinoma: an analysis based on 10-year follow-up
publisher	BMC
publishDate	2021
url	https://doaj.org/article/d57305fc8e9644b699be7a0a99810f3e
work_keys_str_mv	AT leiwang efficacyofconcurrentchemoradiotherapyinsubgroupsofstageiiinasopharyngealcarcinomaananalysisbasedon10yearfollowup AT zhengwu efficacyofconcurrentchemoradiotherapyinsubgroupsofstageiiinasopharyngealcarcinomaananalysisbasedon10yearfollowup AT wanqincheng efficacyofconcurrentchemoradiotherapyinsubgroupsofstageiiinasopharyngealcarcinomaananalysisbasedon10yearfollowup AT dehuanxie efficacyofconcurrentchemoradiotherapyinsubgroupsofstageiiinasopharyngealcarcinomaananalysisbasedon10yearfollowup AT feifeilin efficacyofconcurrentchemoradiotherapyinsubgroupsofstageiiinasopharyngealcarcinomaananalysisbasedon10yearfollowup AT liangpingxia efficacyofconcurrentchemoradiotherapyinsubgroupsofstageiiinasopharyngealcarcinomaananalysisbasedon10yearfollowup AT yongsu efficacyofconcurrentchemoradiotherapyinsubgroupsofstageiiinasopharyngealcarcinomaananalysisbasedon10yearfollowup
_version_	1718442664510095360

Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up

Ejemplares similares